Intra-Cellular Therapies Showcases Breakthrough Data at European Congress
Oral and poster presentations unveiled key findings from Study 501, which investigated lumateperone 42 mg as an additional treatment for major depressive disorder (MDD).
Another significant aspect was the poster presentations that provided insights from post-hoc analyses of Study 403, focusing on a specific group of patients with MDD or bipolar depression accompanied by anxious distress.
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, recently shared important results from the Phase 3 Study 501 at the 37th European College of Neuropsychopharmacology (ECNP) Congress held in Milan.
Dr. Suresh Durgam, the Executive Vice President and Chief Medical Officer at Intra-Cellular Therapies, expressed his approval of the positive data about lumateperone. He emphasized its promising role as an adjunct therapy for MDD. "The robust efficacy exhibited by lumateperone, along with its strong safety profile, positions CAPLYTA as a potentially essential treatment for a variety of patient populations suffering from MDD," Dr. Durgam said.
Below are the specifics of the presentations:
Highlights from Study 501
Oral Presentation: "Adjunctive Lumateperone Significantly Improves Symptoms of Major Depressive Disorder: Topline Results From a Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial." Scheduled for Monday, 15:00 - 16:20 CEST.
Poster Presentation: P2127 – "Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomised, Double-Blind, Phase 3 Trial." Takes place on Monday, from 12:35 to 14:00 CEST.
Insights from Study 403
Poster Presentation P2113 highlights "Lumateperone in the Treatment of Patients With Major Depressive Disorder and Bipolar Disorder With Anxious Distress and Mixed Features," occurring Monday from 12:35 to 14:00 CEST.
Another poster, P2096, reviews "Lumateperone in the Treatment of Major Depressive Disorder and Bipolar Depression With Mixed Features: Efficacy Across Symptoms," scheduled for the same time period.
In Study 501, lumateperone achieved its primary endpoint by showing a significant change from baseline, as assessed by the Montgomery Asberg Depression Rating Scale (MADRS) total score at Week 6 compared to placebo, resulting in a reduction of 4.9 points (p < 0.0001; Cohen’s d effect size (ES)= 0.61). This positive effect was observed as early as Week 1, with improvements continuing throughout the trial. Additionally, substantial secondary endpoints were met in clinician-rated metrics on the Clinical Global Impression Scale for Severity of Illness (CGI-S).
A patient-reported measure, the Quick Inventory of Depressive Symptomatology Self Report scale (QIDS), also showed significant improvements in depressive symptoms (p < 0.0001). The safety profile appeared consistent with earlier studies examining lumateperone for bipolar depression and schizophrenia, indicating stable metabolic parameters such as glucose and cholesterol levels.
Study 502 further supported these findings, confirming that lumateperone 42 mg combined with an antidepressant met both primary and key secondary efficacy endpoints while being safe and well-tolerated in patients not responding adequately to standard antidepressant treatment. More details from Study 502 will be disclosed at upcoming conferences.
Study 403 expanded on lumateperone's effectiveness in patients with either MDD or bipolar depression exhibiting mixed features, shedding light on these complex diagnoses through focused analyses.
Poster #2113 centered on a post-hoc analysis involving patients meeting DSM-5 criteria for anxious distress, further showcasing lumateperone’s potential in reducing depressive symptoms and severity in this vulnerable group.
Additionally, Poster #2096 provided an analysis of MADRS individual items, illustrating lumateperone's broad-spectrum efficacy across various depressive symptoms.
Understanding Major Depressive Disorder
Major Depressive Disorder (MDD) impacts millions each year in the U.S., significantly diminishing individuals' quality of life and overall functioning. Symptoms can include profound sadness, a sense of hopelessness, and cognitive difficulties. Sadly, many patients experience treatment resistance with first-line therapies.
CAPLYTA® (lumateperone) is already approved for treating schizophrenia and depressive episodes related to bipolar disorder. It represents an important addition to treatment options for patients facing complex mood disorders.
Safety Information for Patients
CAPLYTA comes with serious safety warnings. Notably, elderly patients with dementia-related psychosis should not use it due to an increased risk of mortality. Moreover, patients require careful monitoring for potential side effects, including heightened suicidal thoughts often associated with antidepressant treatments.
Frequently Asked Questions
What is lumateperone used for?
Lumateperone (CAPLYTA) is primarily indicated for treating schizophrenia and depressive episodes associated with bipolar disorder.
What were the key findings from Study 501?
Study 501 demonstrated that lumateperone significantly improves MDD symptoms compared to placebo, achieving crucial efficacy metrics.
How does lumateperone compare to traditional antidepressants?
Lumateperone shows robust efficacy while maintaining a favorable safety and tolerability profile, making it a promising adjunct treatment option.
Are there any notable side effects of CAPLYTA?
Common side effects include sedation, dizziness, and nausea. Patients should be monitored for these and other potential adverse reactions.
What are the next steps for Intra-Cellular Therapies?
The company plans to submit a supplemental New Drug Application (sNDA) for lumateperone's role in treating MDD later this year.
